BLAInjectionInjectablePriority Review
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LUCENTIS (ranibizumab) by Roche is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2006.
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUCENTIS (ranibizumab) is a monoclonal antibody fragment that inhibits vascular endothelial growth factor (VEGF) to treat neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Administered by intravitreal injection, it slows vision loss and can improve visual acuity by blocking abnormal blood vessel growth in the eye.
$0.004BPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with modest Part D volume (1,651 claims in 2023); commercial teams likely focused on managed care defense and biosimilar transition planning.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Started Nov 2025
250 enrolled
Neovascular Age-related Macular Degeneration
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Started Sep 2025
266 enrolled
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
Started Oct 2024
406 enrolled
Diabetic Macular Edema (DME)
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Started Jun 2024
68 enrolled
Neovascular Age-related Macular DegenerationnAMD
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Started Dec 2023
0Neovascular Age-Related Macular Degeneration
Worked on LUCENTIS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.